CN115335052A - 与抗cd38治疗剂组合以抑制二氢乳清酸脱氢酶的方法和组合物 - Google Patents

与抗cd38治疗剂组合以抑制二氢乳清酸脱氢酶的方法和组合物 Download PDF

Info

Publication number
CN115335052A
CN115335052A CN202080095284.0A CN202080095284A CN115335052A CN 115335052 A CN115335052 A CN 115335052A CN 202080095284 A CN202080095284 A CN 202080095284A CN 115335052 A CN115335052 A CN 115335052A
Authority
CN
China
Prior art keywords
halogen
pharmaceutical composition
hydrogen
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095284.0A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·C·伯德
艾琳·赫特林
奥拉·A·厄格玛尔
玛丽亚·L·约翰逊
苏席拉·特里丹达帕尼
查德·E·班尼特
桑迪普·马胡卡·维布特
托马斯·E·古德温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Hendrix College
Original Assignee
Ohio State Innovation Foundation
Hendrix College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation, Hendrix College filed Critical Ohio State Innovation Foundation
Publication of CN115335052A publication Critical patent/CN115335052A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080095284.0A 2019-12-26 2020-12-26 与抗cd38治疗剂组合以抑制二氢乳清酸脱氢酶的方法和组合物 Pending CN115335052A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953860P 2019-12-26 2019-12-26
US62/953,860 2019-12-26
PCT/US2020/067074 WO2021134045A1 (en) 2019-12-26 2020-12-26 Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent

Publications (1)

Publication Number Publication Date
CN115335052A true CN115335052A (zh) 2022-11-11

Family

ID=76575158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095284.0A Pending CN115335052A (zh) 2019-12-26 2020-12-26 与抗cd38治疗剂组合以抑制二氢乳清酸脱氢酶的方法和组合物

Country Status (8)

Country Link
US (1) US20230303710A1 (https=)
EP (1) EP4081219A4 (https=)
JP (2) JP7736275B2 (https=)
KR (1) KR20220133198A (https=)
CN (1) CN115335052A (https=)
AU (1) AU2020412805A1 (https=)
CA (1) CA3165475A1 (https=)
WO (1) WO2021134045A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021134042A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
CN117915938A (zh) * 2021-06-30 2024-04-19 俄亥俄州国家创新基金会 用于与抗cd47-sirpα治疗剂组合抑制二氢乳清酸脱氢酶的方法和组合物
EP4436579A4 (en) * 2021-11-22 2025-10-22 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM IN CONJUNCTION WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIA ACTIONS
WO2025202415A1 (en) * 2024-03-28 2025-10-02 Institut National de la Santé et de la Recherche Médicale Dhodh inhibitors for use in the chronopharmacoligical treatment and prevention of obesity and obesity-related metabolic disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025457A1 (en) * 2004-07-28 2006-02-02 Muller George W Isoindoline compounds and methods of their use
US20130101608A1 (en) * 2010-06-15 2013-04-25 Genmab A/S Human antibody drug conjugates against tissue factor
US20210253531A1 (en) * 2018-06-22 2021-08-19 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
US11096934B2 (en) * 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
JP6961879B2 (ja) * 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
WO2018015498A1 (en) * 2016-07-20 2018-01-25 Hybrigenics Sa Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
US20200121815A1 (en) 2017-07-31 2020-04-23 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
US20230089524A1 (en) * 2019-12-26 2023-03-23 Ohio State Innovation Foundation Compositions for use in the inhibition of dihydroorotate dehydrogenase
WO2021134042A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
US20230109418A1 (en) * 2019-12-26 2023-04-06 Ohio State Innovation Foundation Compositions for use for the inhibition of dihydroorotate dehydrogenase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025457A1 (en) * 2004-07-28 2006-02-02 Muller George W Isoindoline compounds and methods of their use
US20130101608A1 (en) * 2010-06-15 2013-04-25 Genmab A/S Human antibody drug conjugates against tissue factor
US20210253531A1 (en) * 2018-06-22 2021-08-19 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Also Published As

Publication number Publication date
CA3165475A1 (en) 2021-07-01
JP2023508938A (ja) 2023-03-06
EP4081219A4 (en) 2024-01-17
JP2025186252A (ja) 2025-12-23
US20230303710A1 (en) 2023-09-28
JP7736275B2 (ja) 2025-09-09
WO2021134045A1 (en) 2021-07-01
AU2020412805A1 (en) 2022-07-14
EP4081219A1 (en) 2022-11-02
KR20220133198A (ko) 2022-10-04

Similar Documents

Publication Publication Date Title
CN112672744B (zh) 抑制二氢乳清酸脱氢酶的方法和组合物
JP7736275B2 (ja) 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
US20240325373A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpa therapeutic agent
HK40082914A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
US20240018108A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
US20230109418A1 (en) Compositions for use for the inhibition of dihydroorotate dehydrogenase
US20230089524A1 (en) Compositions for use in the inhibition of dihydroorotate dehydrogenase
HK40113342A (zh) 用於与抗cd47-sirpα治疗剂组合抑制二氢乳清酸脱氢酶的方法和组合物
KR102956115B1 (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물
CN115361948B (en) Methods and compositions for inhibiting dihydroorotate dehydrogenase
HK40043086A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40043086B (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40084674A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082914

Country of ref document: HK